10.51 USD
▲+0.06+4.37%
盘后 9.95 -1.19%
2026-08-03
市值
$770.07M
市盈率
—
EPS
-0.97
股息率
—
52 周区间
4.35 – 11.36
成交量
1.07M
Beta
-0.50
目标价
20.50
52W 低 4.3552W 高 11.36
价格走势
公司简介
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery pl...